Literature DB >> 26637430

Novel approaches to treating type 2 diabetes.

Michael A Nauck1.   

Abstract

Entities:  

Keywords:  Future therapy; Glucose-lowering therapy; New mechanisms; Pharmacotherapy; Type 2 diabetes

Mesh：

Substances：

Year:  2015        PMID： 26637430     DOI： 10.1007/s00125-015-3823-1

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  10 in total

1.  Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors.

Authors:  Kyle W Sloop; Julia Xiao-Chun Cao; Angela M Siesky; Hong Yan Zhang; Diane M Bodenmiller; Amy L Cox; Steven J Jacobs; Julie S Moyers; Rebecca A Owens; Aaron D Showalter; Martin B Brenner; Achim Raap; Jesper Gromada; Brian R Berridge; David K B Monteith; Niels Porksen; Robert A McKay; Brett P Monia; Sanjay Bhanot; Lynnetta M Watts; M Dodson Michael
Journal:  J Clin Invest       Date:  2004-06       Impact factor: 14.808

2.  The glucagon receptor is required for the adaptive metabolic response to fasting.

Authors:  Christine Longuet; Elaine M Sinclair; Adriano Maida; Laurie L Baggio; Marlena Maziarz; Maureen J Charron; Daniel J Drucker
Journal:  Cell Metab       Date:  2008-11       Impact factor: 27.287

3.  Metabolic manifestations of insulin deficiency do not occur without glucagon action.

Authors:  Young Lee; Eric D Berglund; May-yun Wang; Xiaorong Fu; Xinxin Yu; Maureen J Charron; Shawn C Burgess; Roger H Unger
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-13       Impact factor: 11.205

4.  GLP-1R agonists promote normal and neoplastic intestinal growth through mechanisms requiring Fgf7.

Authors:  Jacqueline A Koehler; Laurie L Baggio; Bernardo Yusta; Christine Longuet; Katherine J Rowland; Xiemin Cao; Dianne Holland; Patricia L Brubaker; Daniel J Drucker
Journal:  Cell Metab       Date:  2015-03-03       Impact factor: 27.287

5.  Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice.

Authors:  R W Gelling; X Q Du; D S Dichmann; J Romer; H Huang; L Cui; S Obici; B Tang; J J Holst; C Fledelius; P B Johansen; L Rossetti; L A Jelicks; P Serup; E Nishimura; M J Charron
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-24       Impact factor: 11.205

6.  Glucokinase mutations associated with non-insulin-dependent (type 2) diabetes mellitus have decreased enzymatic activity: implications for structure/function relationships.

Authors:  M Gidh-Jain; J Takeda; L Z Xu; A J Lange; N Vionnet; M Stoffel; P Froguel; G Velho; F Sun; D Cohen
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205

7.  Discovery of a novel glucagon receptor antagonist N-[(4-{(1S)-1-[3-(3, 5-dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl]ethyl}phenyl)carbonyl]-β-alanine (MK-0893) for the treatment of type II diabetes.

Authors:  Yusheng Xiong; Jian Guo; Mari R Candelore; Rui Liang; Corey Miller; Qing Dallas-Yang; Guoqiang Jiang; Peggy E McCann; Sajjad A Qureshi; Xinchun Tong; Shiyao Sherrie Xu; Jackie Shang; Stella H Vincent; Laurie M Tota; Michael J Wright; Xiaodong Yang; Bei B Zhang; James R Tata; Emma R Parmee
Journal:  J Med Chem       Date:  2012-06-28       Impact factor: 8.039

8.  Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetes.

Authors:  Gary E Meininger; Russell Scott; Maria Alba; Yue Shentu; Edmund Luo; Himal Amin; Michael J Davies; Keith D Kaufman; Barry J Goldstein
Journal:  Diabetes Care       Date:  2011-10-12       Impact factor: 19.112

9.  Cardiomyocyte glucagon receptor signaling modulates outcomes in mice with experimental myocardial infarction.

Authors:  Safina Ali; John R Ussher; Laurie L Baggio; M Golam Kabir; Maureen J Charron; Olga Ilkayeva; Christopher B Newgard; Daniel J Drucker
Journal:  Mol Metab       Date:  2014-11-29       Impact factor: 7.422

Review 10.  G protein-coupled receptors as new therapeutic targets for type 2 diabetes.

Authors:  Frank Reimann; Fiona M Gribble
Journal:  Diabetologia       Date:  2015-12-12       Impact factor: 10.122
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.